Long Term Follow up of the Resort Study (E4402): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Low Tumor Burden Follicular Lymphoma

MLA

Kahl, Brad S., et al. “Long Term Follow up of the Resort Study (E4402): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Low Tumor Burden Follicular Lymphoma.” Blood, vol. 138, no. Supplement 1, Nov. 2021, p. 815. EBSCOhost, https://doi.org/10.1182/blood-2021-152976.

APA

Kahl, B. S., Hong, F., Peterson, C., Swinnen, L. J., Habermann, T. M., Schuster, S. J., Weiss, M., Fishkin, P. A. S., Ehmann, W. C., Fenske, T. S., & Williams, M. E. (2021). Long Term Follow up of the Resort Study (E4402): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Low Tumor Burden Follicular Lymphoma. Blood, 138(Supplement 1), 815. https://doi.org/10.1182/blood-2021-152976

Chicago

Kahl, Brad S., Fangxin Hong, Christopher Peterson, Lode J. Swinnen, Thomas M. Habermann, Stephen J Schuster, Matthias Weiss, et al. 2021. “Long Term Follow up of the Resort Study (E4402): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Low Tumor Burden Follicular Lymphoma.” Blood 138 (Supplement 1): 815. doi:10.1182/blood-2021-152976.